Advanced Renal Cell Carcinoma
Advertisement
The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.
Improved PFS was associated with negative surgical margins and no 30-day surgical complications, plus pathologic downstaging.
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Belzutifan improves PFS in adult patients with advanced RCC who have progressed on previous PD-1/PD-L1 or VEGF-TKI therapies.
Researchers investigated the impact of duration of exposure to antiangiogenics on immunotherapy outcomes in metastatic ccRCC.
Researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy as a first-line mRCC treatment.
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Researchers summarized the survival outcomes of patients with mRCC treated with CN after IO-based perioperative treatments.
Research presented at KCRS23 characterized patients with an OR in the lenvatinib plus pembrolizumab arm of the CLEAR study.
At KCRS23, researchers presented their data on the differences in clinical outcomes in patients with synchronous and metachro
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
The IMmotion150, IMmotion151, and JAVELIN Renal 101 trials were assessed for OS, PFS, and ORR of anti-PD-L1 combinations.
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.
CBM588 may improve clinical outcomes for patients with mRCC when combined with the cabozantinib plus nivolumab.
A study from ASCO 2023 surveyed patients to determine how they prioritize their treatment selection for mRCC.
Researchers conducted an exploratory follow-up analysis of HRQoL in treament with nivolumab plus cabozantinib vs sunitinib.
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.